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syndrome
Dagmar Vondrakova, Petr Ostadal* and Andreas Kruger
Abstract
Background: Intensive statin therapy decreases mortality and incidence of coronary events in patients after acute 
coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during 
ACS. The immediate influence of lipid levels by high-dose statin therapy initiated at admission in ACS patients is, 
however, not clear.
Methods: We have analyzed a group of 114 patients with ACS (mean age 63.7; females 25.4%). Atorvastatin 80 mg was 
administered at admission and then once daily for the rest of hospitalization. The levels of total cholesterol (TC), LDL-
cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) were measured at admission (D0), and then every 
morning of hospitalization (D1, D2).
Results: The mean entry values (D0) of TC, LDL, HDL and TG (in mmol/L) were 5.24, 3.26, 1.07 and 1.31, respectively. The 
therapy with atorvastatin 80 mg resulted in a decrease of TC levels in the first morning (D1) by 6.1% and in the second 
morning (D2) by 13.2% (p < 0.001 for all comparisons with the entry value D0); LDL was decreased by 5.8% (D1) and 
15.6% (D2) (p < 0.001 vs. D0); the level of HDL was decreased by 7.5% (D1) and 12.1% (D2) (p < 0.001 vs. D0). In contrast, 
the TG level was higher in the first morning (D1) by 20.6% and in the following morning (D2) by 25.5% (p < 0.05 vs. D0).
Conclusions: We have shown that intensive statin therapy started at admission in ACS patients has a highly significant, 
immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL 
and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-
term treatment of ACS patients.
Introduction
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, have been for two decades
successfully used in the therapy of hypercholesterolemia
and stable ischemic heart disease. During the recent
years, several large clinical trials were presented showing
a beneficial effect of statin therapy started in acute coro-
nary syndrome (ACS) patients after clinical stabilization
or before discharge [1-3]. Moreover, it has been shown
that intensive (high-dose) statin therapy is superior to
standard-dose: in the meta-analysis intensive statin ther-
apy decreased not only the incidence of cardiovascular
events but also total mortality in patients after ACS with-
out increase of serious side effects [4,5]. Intensive statin
therapy is therefore currently widely recommended in
patients after ACS.
Besides lipid-lowering effect activity, however, statins
exhibit also other effects: they suppress inflammation,
decrease oxidative stress, improve endothelial dysfunc-
tion, protect against ischemia damage, have a slight anti-
thrombotic property etc. [6]. Statins may, therefore,
favourably modulate several pathways playing an impor-
tant role in the pathogenesis of ACS and these effects
could be used not only in early secondary prevention
after ACS but also in the therapy of unstable ACS patients
at admission. Analyses of ACS registries have shown a
beneficial effect of statin-therapy initiation within 24
hours of hospital admission [7] and recently also small
clinical studies were published showing a promising
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effect of statin administered in the first-line therapy of
ACS [8].
During the early phases of ACS, rapid changes occur in
the serum levels of markers of myocardial necrosis,
inflammation, oxidative stress, and others. Interestingly,
only a limited number of authors focused on lipid levels
in ACS patients; these studies which were mostly smaller
in the size of population or did not use contemporary rec-
ommendations for ACS management including coronary
interventions have shown a decrease in total and LDL-
cholesterol [9-12]. Analysis of the baseline data from the
LUNAR study has, however, demonstrated in a large ACS
population treated according to current guidelines that
there are only clinically insignificant spontaneous
changes in the lipid parameters (total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglycerides) in the
first four days of ACS [13]. It is, however, still not clear
whether the lipid levels in the early phase of ACS may be
influenced by intensive statin treatment.
Up to the best knowledge, this is the first study focusing
on the immediate effect of high-dose statin administered
in the first-line therapy of ACS on the lipid parameters.
Methods
Subjects
The study protocol was approved by the institutional eth-
ics committee; written informed consent was obtained
from all participating subjects. One-hundred and four-
teen consecutive patients admitted to the Coronary Care
Unit for ACS were enrolled in this study. Eligible patients
with ST elevation ACS had rest chest pain less than 12
hours before admission and ≥ 1 mm ST-segment eleva-
tion in two or more contiguous leads or new left bundle
branch block on ECG. Eligible patients with non-ST ele-
vation ACS had rest chest pain during the past 24 hours
and ≥ 1 mm ST segment depression or negative T waves
in two or more contiguous leads. Exclusion criteria were:
concomitant active liver disease or known persistent ele-
vation of transaminases more than three times above the
upper limit, the patient is already on high-dose statin
therapy, known allergy for atorvastatin or intolerance of
high-dose atorvastatin, disability of oral drug administra-
tion, pregnancy or nursing, women of fertile age without
effective contraception, suspicions of muscle disease,
such as myositis, and subjects younger than 18 years.
At admission for ACS, blood samples were taken for
examination of the baseline fasting or non-fasting serum
lipid parameters: total cholesterol (TC), triglycerides
(TG), LDL-cholesterol (LDL-C), and HDL-cholesterol
(HDL-C); fasting lipid levels were then measured every
morning of hospitalization. Atorvastatin 80 mg (Sortis,
Pfizer) was administered immediately after samples for
baseline lipid assessment were obtained, and then once
daily for the rest of the study, if tolerated.
All patients underwent urgent coronary angiography
and percutaneous coronary intervention, if necessary.
Standard therapy included aspirin, heparin, low-molecu-
lar-weight heparin or fondaparinux, and clopidogrel in all
patients, nitrates, beta-blockers, and angiotensin-con-
verting-enzyme inhibitors according to the clinical condi-
tions.
Laboratory assays
Blood samples for lipid level analysis were taken at admis-
sion and then on the first and second morning of hospi-
talization. TC, LDL-C, HDL-C, and TG levels were
directly measured with UNICEL DxC 800 (Beckman
Coulter, USA) automatic analyzer system immediately
after blood samples were obtained.
Statistical analysis
The values are expressed as means ± standard error (SE).
Statistical analysis of lipid level differences was per-
formed by paired two-tail t-test. P < 0.05 was considered
to be statistically significant.
Results
From January to December 2009 114 patients with ACS
were recruited. The mean age was 63.7, majority were
males (75%), ST-elevation ACS was experienced by 65%
of enrolled subjects (Table 1). The mean baseline levels
(D0) of TC, LDL-C, HDL-C and TG were 5.24 ± 0.07, 3.26
± 0.07, 1.07 ± 0.02, and 1.31 ± 0.07 mmol/L, respectively.
The administration of atorvastatin 80 mg resulted in a
decrease of TC levels in the first morning of hospitaliza-
tion (D1) to 4.92 ± 0.07 and in the second morning (D2)
to 4.55 ± 0.08 (mmol/L; P < 0.001 for all comparisons
with D0) (Figure 1A); LDL-C was decreased to 3.07 ± 0.07
(D1) and to 2.75 ± 0.08 (D2) (mmol/L; P < 0.001 for all
comparisons with D0) (Figure 1B); the level of HDL-C
was reduced to 0.99 ± 0.02 (D1) and 0.94 ± 0.02 (D2)
Table 1: Baseline characteristics of the study group.
Mean age (years) 63.7
Female 25.0
History of
CAD 28.0
diabetes 29.8
hypertension 67.5
Current smokers 48.2
Type of ACS
STE 65.0
NSTE 35.0
Results are expressed in per cent if not stated differently. CAD, 
coronary artery disease; ACS, acute coronary syndrome; STE, ST-
elevation on electrocardiogram; NSTE, non-ST-elevation on 
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(mmol/L; P < 0.001 for all comparisons with D0) (Figure
1C). In contrast, the TG level was increased to 1.58 ± 0.06
in D1 and 1.64 ± 0.07 in D2 (mmol/L; P < 0.05 for all com-
parisons with D0) (Figure 1D). The therapy with atorvas-
tatin 80 mg was well tolerated: we did not register any
case of myopathy, myositis, rhabdomyolysis or statin-
related elevation of alanine aminotransferase; creatine
phosphokinase and aspartate aminotransferase were ele-
vated in most subjects as a result of myocardial necrosis.
Discussion
The major observation of this study is that atorvastatin 80
mg significantly influences the lipid parameters already
within one or two days, if administered in the first-line
therapy of ACS. Furthermore, we have shown that an
acute effect of intensive atorvastatin therapy on HDL-C
a n d  T G  i s  o p p o s i t e  t o  l o n g - t e r m  t r e a t m e n t :  w e  h a v e
observed an acute decrease in HDL-C and an acute
increase in TG levels.
Current evidence for the acute effect of statins on lipid
levels in ACS patients is poor. Present results are in
cagreement with our previous study showing rapid
reduction of TC and LDL-C after administration of flu-
vastatin 80 mg in ACS patients [6]. A decrease of TC and
LDL-C has been reported also by Michelena et al. [14]
after three days of high-dose simvastatin therapy in stable
high-risk patients, by Zhou et al. [15] after one-week
atorvastatin therapy of ACS patients, by Marchesi et al.
[16] after one-week atorvastatin therapy in women with
hypercholesterolemia, and by Li et al. [17] after two
Figure 1 Serum levels of lipid parameters in early phases of acute coronary syndrome in patients (N = 114) with atorvastatin 80 mg therapy 
initiated at admission. Serum lipids were measured at admission (D0), first morning of hospitalization (D1), and second morning of hospitalization 
(D2). Panel A: levels of total cholesterol. Panel B: levels of LDL-cholesterol. Panel C: levels of HDL-cholesterol. Panel D: levels of triglycerides.
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weeks of simvastatin treatment in patients with dyslipi-
demia. On the other hand, Tsunekawa et al. [18] did not
observe any difference in blood lipids after a three-day
therapy with cerivastatin in elderly diabetic patients; this
discrepancy can be at least partly explained by the low
dose of cerivastatin (0.15 mg/day) as well as by different
patient's characteristics.
In our previous study we observed only an insignificant
trend to acute decrease in HDL-C as a result of fluvasta-
tin 80 mg treatment in ACS patients and the TG level in
this study was not changed [6]; this discordance with the
present observation may be explained by the less potent
lipid-lowering effect of fluvastatin in comparison with
atorvastatin, as well as by the smaller sample size and
shorter follow-up. In other studies focusing on the short-
term effect of statins on the lipid profile that were carried
out with stable patients and on lipid levels measured after
three to fourteen days of therapy HDL-C and TG were
not significantly changed [14-17]. We have no clear
explanation for the marked increase in TG levels in our
study, despite the fact that the baseline sample was mostly
taken in non-fasting conditions whereas the D1 and D2
samples were fasting.
The major limitation of the present study is the absence
of control group. It has been, however, recently reported
that the spontaneous changes in lipid profile during the
first days of ACS in patients managed according to cur-
rent recommendations are only borderline or statistically
not significant [13]; it can be, therefore, anticipated that
the lipid profile in statin non-users will be similar to the
baseline levels. Another limitation comes from the small
size of the studied population; however, the observed
changes in lipid levels are statistically highly significant.
Furthermore, we have determined the lipid profile in
non-fasting patients in the baseline and then in fasting
conditions in D1 and D2. Non-fasting lipid measure-
ments were, however, used also in other studies focusing
on the rapid effect of statins [6,12,14] and we did not
observe TG levels high enough to interfere with the anal-
ysis of other lipid parameters; moreover, surprisingly, we
have found that after administration of atorvastatin the
fasting TG levels were higher than the non-fasting base-
line value.
It can be concluded that intensive atorvastatin therapy
initiated at admission of patients with ACS has a prompt
acute effect on the lipid profile and that this effect differs
from the long-term statin treatment. Further research is,
however, needed to confirm and explain these results.
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